Researchers examined data on more than 600,000 people, comparing patients who were prescribed aspirin over a long period (average duration was 7.7 years) and patients who were not aspirin users.
They found that long-term aspirin users showed a:
● 47 percent reduction in liver and oesophageal cancer incidence
● 38 percent reduction in gastric cancer incidence
● 34 percent reduction in pancreatic cancer incidence
● 24 percent reduction in colorectal cancer incidence
“What should be noted is the significance of the results for cancers within the digestive tract, where the reductions in cancer incidence were all very substantial, especially for liver and oesophageal cancer,” said Professor Kelvin Tsoi, lead researcher from the Chinese University of Hong Kong.
More articles on healthcare quality:
CDC reports 1st pediatric flu death for 2017-2018 flu season
Flu vaccine improves outcome rate for other infections: 6 study findings
Top 10 infection control stories, Oct. 23-27
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
